# Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer

> **NCT02623621** · — · COMPLETED · sponsor: **Azienda Ospedaliero, Universitaria Pisana** · enrollment: 103 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** chemotherapy plus bevacizumab

## Key facts

- **NCT ID:** NCT02623621
- **Lead sponsor:** Azienda Ospedaliero, Universitaria Pisana
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-10
- **Final completion:** 2017-12
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2017-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623621, "Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02623621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*